Company intelligence / Profile preview

Orano Med

Ownership: Private
Employees: ~170
Development stage: Phase 2

Overview

Phase II clinical trial of their most advanced drug, AlphaMedix, is nearing completion. AlphaMedix received Breakthrough Designation from the FDA in 2024 for GEP-NETs tumors.

Therapeutic areas: Oncology
Modalities: Targeted Alpha Therapy (TAT)Radioligand TherapyLead-212 (²¹²Pb) based therapies
Industry: Biotech

Drug pipeline

11 assets

212Pb-TCMC-trastuzumab

10 more assets in the full pipeline.

Request access →

Partnerships

Molecular Partners

Beyond the preview

Go deeper on Orano Med.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orano Med.

Explore the full profile